Drug Profile
Research programme: cytomegalovirus vaccine - CAP-CMV
Alternative Names: CAP-CMV-001Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator CAP-CMV
- Class Cytomegalovirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Cytomegalovirus infections(Prevention) in Germany (Parenteral)
- 09 Jan 2014 Preclinical trials in Cytomegalovirus infections (prevention in patients undergoing solid organ transplantation) in Germany (Parenteral)